15 completed. 15 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 15 |
| Phase 2 | 3 | Completed 3 |
Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 CVnCoV Vaccine, Placebo - Coronavirus, Covid19 | Phase 3 | Completed | CureVac | 2357 | 2020-12-23 | 2023-10-06 |
| Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) Fluvoxamine, Placebo - Covid19, Coronavirus | Phase 3 | Completed | Washington University School of Medicine | 670 | 2020-12-22 | 2022-10-31 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study Plasma, Standard Therapy - Coronavirus, Coronavirus Infection | Phase 2 / Phase 3 | Completed | Universidad del Rosario | 92 | 2020-08-08 | 2020-11-27 |
| Investigating a Vaccine Against COVID-19 ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost - Coronavirus | Phase 2 / Phase 3 | Completed | University of Oxford | 10811 | 2020-05-28 | 2025-09-03 |
| Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults pathogen reduced SARS-CoV-2 convalescent plasma, Placebo - COVID-19, Coronavirus | Phase 3 | Completed | Vanderbilt University Medical Center | 974 | 2020-04-24 | 2022-11-03 |
| Sevoflurane in COVID-19 ARDS (SevCov) Sevoflurane, Intravenous drug - ARDS, Human, Coronavirus | Phase 3 | Completed | University of Zurich | 68 | 2020-04-23 | 2021-07-19 |
| Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial Colchicine, Interferon-Beta, Aspirin - Coronavirus, Severe Acute Respiratory Syndrome | Phase 3 | Completed | Population Health Research Institute | 6667 | 2020-04-21 | 2024-01-11 |
| Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19 Chloroquine, Hydroxychloroquine, standard care - COVID, COVID-19 | Phase 3 | Completed | Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva | 142 | 2020-04-16 | 2021-05-12 |
| Convalescent Plasma Collection and Treatment in Pediatrics and Adults Convalescent Plasma - COVID19, Coronavirus Infection | Phase 3 | Completed | West Virginia University | 117 | 2020-04-16 | 2026-05-29 |
| COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) cholecalciferol 200,000 IU, cholecalciferol 50,000 IU - Coronavirus | Phase 3 | Completed | University Hospital, Angers | 260 | 2020-04-15 | 2021-04-30 |
| Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease Hydroxychloroquine, Placebo - Coronavirus, Acute Respiratory Infection | Phase 3 | Completed | Massachusetts General Hospital | 479 | 2020-04-02 | 2021-03-17 |
| Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 Hydroxychloroquine, Placebo - Corona Virus Infection, Acute Respiratory Distress Syndrome | Phase 3 | Completed | University of Minnesota | 1312 | 2020-03-17 | 2021-05-13 |
| Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19 Hydroxychloroquine - Pneumonia, Pneumocystis, Coronavirus | Phase 3 | Completed | Shanghai Public Health Clinical Center | 30 | 2020-02-06 | 2020-04-13 |
| Lessening Organ Dysfunction With VITamin C Vitamin C, Control - Sepsis, Vitamin C | Phase 3 | Completed | Université de Sherbrooke | 872 | 2018-11-08 | 2022-04-04 |
Coronavirus Infections (15) · COVID-19 (14) · Severe Acute Respiratory Syndrome (5) · RNA Virus Infections (2) · Respiratory Distress Syndrome (2) · Virus Diseases (2) · Coronaviridae Infections (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Pneumocystis (1) · Pneumonia, Viral (1) · Sepsis (1)
Infections (15) · Coronaviridae Infections (14) · Lung Diseases (14) · Nidovirales Infections (14) · Respiratory Tract Diseases (14) · Respiratory Tract Infections (14) · Pneumonia (13) · Pneumonia, Viral (13) · RNA Virus Infections (13) · Virus Diseases (13) · Respiration Disorders (2) · Bacterial Infections and Mycoses (1) · Inflammation (1) · Lung Diseases, Fungal (1) · Mycoses (1)
Hydroxychloroquine (4) · Standard of Care (2) · Ascorbic Acid (1) · Aspirin (1) · COVID-19 Serotherapy (1) · CVnCoV COVID-19 vaccine (1) · ChAdOx1 nCoV-19 (1) · Chloroquine (1) · Cholecalciferol (1) · Colchicine (1) · Fluvoxamine (1) · Infusion Pumps (1) · Interferon-beta (1) · Meningococcal Vaccines (1) · PRIME protocol (1)
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva (1) · CureVac (1) · Massachusetts General Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Population Health Research Institute (1) · Shanghai Public Health Clinical Center (1) · Universidad del Rosario (1) · University Hospital, Angers (1) · University of Minnesota (1) · University of Oxford (1) · University of Zurich (1) · Université de Sherbrooke (1) · Vanderbilt University Medical Center (1) · Washington University School of Medicine (1) · West Virginia University (1)
United States (6) · Canada (5) · Brazil (3) · Colombia (2) · Philippines (2) · South Africa (2) · Argentina (1) · China (1) · Ecuador (1) · Egypt (1) · France (1) · Germany (1) · Guatemala (1) · India (1) · Mexico (1)
Andrew Pollard, Prof (1) · Beatrice Beck Schimmer, Prof (1) · Boyd Taylor Thompson, MD (1) · Brian Peppers, DO, PhD (1) · David Boulware, MD, MPH (1) · David Smith, MD, MAS (1) · Emilie Belley-Cote, MD PhD (1) · John Eikelboom, MBBS MSc (1) · Juan M Anaya Cabrera, MD, PhD (1) · Neill Adhikari, MDCM FRCPC MSc (1) · Richard Whitlock, MD PhD (1) · Todd Rice, MD (1)
PMID 31915072, PMID 32391667, PMID 32492293, PMID 32492354, PMID 32673060, PMID 33165621, PMID 33204764, PMID 33220855, PMID 33274360, PMID 33306989, PMID 33335323, PMID 33371905, PMID 33570583, PMID 33617777, PMID 33688640, PMID 33721539, PMID 33743799, PMID 33757717, PMID 33798499, PMID 33907251, PMID 34020705, PMID 34153264, PMID 34473343, PMID 34480858, PMID 34658014, PMID 34981077, PMID 35192543, PMID 35639792, PMID 35704292, PMID 35713300, PMID 35761219, PMID 35780813, PMID 35793677, PMID 35797235, PMID 35995785, PMID 36210483, PMID 36228639, PMID 36228641, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37489818, PMID 37622035, PMID 37650230
3UL1TR002243-04S3 (1)